HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 7 (July)

1. Prevalence of HIV infection in conflict-affected and displaced people in seven sub-Saharan African countries: a systematic review.
   Lancet, 369(9580): 2187-95. [Abstract] [Full-text]
2. Birth attendants trained in "Prevention of Mother-To-Child HIV Transmission" provide care in rural Cameroon, Africa.
   J Midwifery Womens Health, 52(4): 334-41. [Abstract] [Full-text]
3. The HIV-positive traveler.
   Am J Med, 120(7): 574-80. [Abstract] [Full-text]
4. Nursing care of AIDS patients in Uganda.
   J Transcult Nurs, 18(3): 257-64. [Abstract] [Full-text]
5. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
   Pediatrics, 120(1): 100-9. [Abstract] [Full-text]
6. Nature, decay, and spiraling of the effects of fear-inducing arguments and HIV counseling and testing: a meta-analysis of the short- and long-term outcomes of HIV-prevention interventions.
   Health Psychol, 26(4): 496-506. [Abstract] [Full-text]
7. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women.
   Health Psychol, 26(4): 488-95. [Abstract] [Full-text]
8. Conscientiousness predicts disease progression (CD4 number and viral load) in people living with HIV.
   Health Psychol, 26(4): 473-80. [Abstract] [Full-text]
9. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
   J Med Virol, 79(8): 1047-54. [Abstract] [Full-text]
10. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.
    J Med Virol, 79(8): 1040-6. [Abstract] [Full-text]
11. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
    J Med Virol, 79(8): 1033-9. [Abstract] [Full-text]
12. Computational modeling and functional analysis of Herpes simplex virus type-1 thymidine kinase and Escherichia coli cytosine deaminase fusion protein.
    Biochem Biophys Res Commun, 360(1): 46-50. [Abstract] [Full-text]
13. How far will we need to go to reach HIV-infected people in rural South Africa?
    BMC Med, 5: 16. [Abstract] [Full-text]
14. AIDS patients have increased surfactant protein D but normal mannose binding lectin levels in lung fluid.
    Respir Res, 8: 42. [Abstract] [Full-text]
15. Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males.
    Dis Colon Rectum, 50(7): 1011-6. [Abstract] [Full-text]
16. Immunotactoid glomerulonephritis in a child with HIV infection: a case report.
    Pediatr Nephrol, 22(9): 1387-90. [Abstract] [Full-text]
17. HIV entry inhibitors.
    Lancet, 370(9581): 81-8. [Abstract] [Full-text]
18. International perspectives, progress, and future challenges of paediatric HIV infection.
    Lancet, 370(9581): 68-80. [Abstract] [Full-text]
19. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
    Lancet, 370(9581): 59-67. [Abstract] [Full-text]
20. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Lancet, 370(9581): 49-58. [Abstract] [Full-text]
21. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Lancet, 370(9581): 39-48. [Abstract] [Full-text]
22. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
    Lancet, 370(9581): 29-38. [Abstract] [Full-text]
23. Is patients' preferred involvement in health decisions related to outcomes for patients with HIV?
    J Gen Intern Med, 22(8): 1119-24. [Abstract] [Full-text]
24. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    J Med Virol, 79(9): 1261-9. [Abstract] [Full-text]
25. Quasispecies analysis of novel HIV-1 recombinants of subtypes A and G reveals no similarity to the mosaic structure of CRF02_AG.
    J Med Virol, 79(9): 1270-85. [Abstract] [Full-text]
26. Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml.
    J Med Virol, 79(9): 1254-60. [Abstract] [Full-text]
27. Utility of brain biopsy in patients with acquired immunodeficiency syndrome before and after introduction of highly active antiretroviral therapy.
    Neurosurgery, 61(1): 130-40; discussion 140-1. [Abstract] [Full-text]
28. When do simpler sexual behavior data collection techniques suffice? An analysis of consequent uncertainty in HIV acquisition risk estimates.
    Eval Rev, 31(4): 401-12. [Abstract] [Full-text]
29. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients.
    J Acquir Immune Defic Syndr, 45(4): 432-8. [Abstract] [Full-text]
30. The protective effect of circumcision on HIV incidence in rural low-risk men circumcised predominantly by traditional circumcisers in Kenya: two-year follow-up of the Kericho HIV Cohort Study.
    J Acquir Immune Defic Syndr, 45(4): 371-9. [Abstract] [Full-text]
31. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
    J Acquir Immune Defic Syndr, 45(4): 401-10. [Abstract] [Full-text]
32. Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure.
    J Acquir Immune Defic Syndr, 45(4): 411-7. [Abstract] [Full-text]
33. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
    J Acquir Immune Defic Syndr, 45(4): 454-67. [Abstract] [Full-text]
34. User acceptability and feasibility of self-testing with HIV rapid tests.
    J Acquir Immune Defic Syndr, 45(4): 449-53. [Abstract] [Full-text]
35. The relation between symptoms, viral load, and viral load set point in primary HIV infection.
    J Acquir Immune Defic Syndr, 45(4): 445-8. [Abstract] [Full-text]
36. HIV and metabolic syndrome: a comparison with the general population.
    J Acquir Immune Defic Syndr, 45(4): 426-31. [Abstract] [Full-text]
37. The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand.
    J Acquir Immune Defic Syndr, 45(4): 468-75. [Abstract] [Full-text]
38. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
    J Acquir Immune Defic Syndr, 45(4): 439-44. [Abstract] [Full-text]
39. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
    J Acquir Immune Defic Syndr, 45(4): 418-25. [Abstract] [Full-text]
40. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.
    J Acquir Immune Defic Syndr, 45(4): 380-8. [Abstract] [Full-text]
41. HIV-1 Subtype C gag-specific T-cell responses in relation to human leukocyte antigens in a diverse population of HIV-infected Ethiopians.
    J Acquir Immune Defic Syndr, 45(4): 389-400. [Abstract] [Full-text]
42. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Gut, 56(8): 1111-6. [Abstract] [Full-text]
43. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome.
    J Infect, 55(2): 125-35. [Abstract] [Full-text]
44. Predictors of condom use among sexually active persons involved in compulsory national service in Ibadan, Nigeria.
    Health Educ Res, 22(4): 459-72. [Abstract] [Full-text]
45. Cytokines in HIV-associated cardiomyopathy.
    Int J Cardiol, 120(2): 150-7. [Abstract] [Full-text]
46. Thickness of the cervical epithelium of autopsied patients with acquired immunodeficiency syndrome.
    Ann Diagn Pathol, 11(4): 258-61. [Abstract] [Full-text]
47. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Clin Infect Dis, 45(4): 514-7. [Abstract] [Full-text]
48. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy.
    Clin Infect Dis, 45(4): 510-3. [Abstract] [Full-text]
49. HIV type 1 superinfection with a dual-tropic virus and rapid progression to AIDS: a case report.
    Clin Infect Dis, 45(4): 501-9. [Abstract] [Full-text]
50. Thyroid function abnormalities in HIV-infected patients.
    Clin Infect Dis, 45(4): 488-94. [Abstract] [Full-text]
51. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Clin Infect Dis, 45(4): e39-41. [Abstract] [Full-text]
52. HIV-2 RNA dimerization is regulated by intramolecular interactions in vitro.
    RNA, 13(8): 1341-54. [Abstract] [Full-text]
53. Component cognitive and motor processes of the digit symbol test: differential deficits in alcoholism, HIV infection, and their comorbidity.
    Alcohol Clin Exp Res, 31(8): 1315-24. [Abstract] [Full-text]
54. Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling.
    Virus Genes, 35(2): 215-23. [Abstract] [Full-text]
55. Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles.
    Virus Genes, 35(2): 187-93. [Abstract] [Full-text]
56. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
    Virus Genes, 35(2): 167-74. [Abstract] [Full-text]
57. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus.
    Antioxid Redox Signal, 9(8): 1009-34. [Abstract] [Full-text]
58. Darunavir: a second-generation protease inhibitor.
    Am J Health Syst Pharm, 64(15): 1593-602. [Abstract] [Full-text]
59. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.
    J Virol, 81(16): 8793-808. [Abstract] [Full-text]
60. Expression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat model.
    J Virol, 81(16): 8406-11. [Abstract] [Full-text]
61. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction.
    J Virol, 81(16): 8439-50. [Abstract] [Full-text]
62. Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form.
    J Virol, 81(16): 8543-51. [Abstract] [Full-text]
63. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques.
    J Virol, 81(16): 8621-33. [Abstract] [Full-text]
64. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
    J Virol, 81(16): 8507-14. [Abstract] [Full-text]
65. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease.
    J Virol, 81(16): 8838-42. [Abstract] [Full-text]
66. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    J Virol, 81(16): 8533-42. [Abstract] [Full-text]
67. Diagnostic accuracy and clinical utility of a simplified low cost method of counting CD4 cells with flow cytometry in Malawi: diagnostic accuracy study.
    BMJ, 335(7612): 190. [Abstract] [Full-text]
68. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study.
    BMJ, 335(7612): 188. [Abstract] [Full-text]
69. Tonsil epithelial factors may influence oropharyngeal human immunodeficiency virus transmission.
    Am J Pathol, 171(2): 571-9. [Abstract] [Full-text]
70. Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.
    J Theor Biol, 247(4): 804-18. [Abstract] [Full-text]
71. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.
    Lancet, 370(9583): 251-61. [Abstract] [Full-text]
72. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
    Diabetes, 56(8): 2070-7. [Abstract] [Full-text]
73. Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients.
    Vaccine, 25(34): 6310-2. [Abstract] [Full-text]
74. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities.
    CMAJ, 177(3): 257-61. [Abstract] [Full-text]
75. Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons.
    CMAJ, 177(3): 252-6. [Abstract] [Full-text]
76. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.
    J Clin Oncol, 25(22): 3350-6. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.